Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

• Drug: PF-05231023
  
  5 mg IV twice a week for 4 weeks
• Drug: PF-05231023
  
  25 mg IV twice a week for 4 weeks
• Drug: PF-05231023
  
  100 mg IV twice a week for 4 weeks
• Drug: PF-05231023
  
  200 mg IV twice a week for 4 weeks
• Other: Placebo
  
  0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks

• Experimental: Treatment
  
  Interventions:
  

  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
• Placebo Comparator: Placebo
  
  Intervention: Other: Placebo

Inclusion Criteria:

• Male subjects and female subjects of non-childbearing potential between the ages of 30 and 70 years, inclusive, with a historical diagnosis of type 2 diabetes mellitus, diagnosed according to the American Diabetes Association guidelines. Subjects who have other conditions but are well controlled by either diet or medications may be included as well (for example, a subject with high cholesterol level on appropriate treatment is eligible).
• Body Mass Index (BMI) of 25 to 35.5 kg/m2, and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Diagnosis of Type 1 diabetes mellitus.
• Evidence of diabetic complications with significant end organ damage